Dr. Clay Siegall carries on his passion to make the lives of people with cancer better by advancing therapies to care for their needs.
After receiving a B.S. in zoology from the University of Maryland, he graduated from George Washington University with a Ph.D. in genetics. One of his main ambitions has been to displace existing therapies with more effective targeted medicines.
Dr. Siegall gave the details about his strong pull towards medicine and technology working together to overcome disease, in an interview(http://inspirery.com/dr-clay-siegall). He added that his interest in cancer treatment began while he was a student studying zoology.
According to Dr. Siegall he was inspired to launch his own business after observing a family member’s severe course of treatment. It was at that time he decided there must be better remedies. He also has a preference for working for himself over working for others.
He founded Seattle Genetics in 1998 and talked about how selling their own proprietary drugs, collaborating with partners and licensing agreements have all led the company to become profitable. He added profitability was achieved roughly 10 years after the company went public.
Dr. Siegall also revealed the company’s sales staff and the number of its unique products have made it easier to obtain customers.
What’s more, he imparted some understanding and knowledge of how hard work, such as working fiercely and with great single-mindedness, helped him succeed and can help other entrepreneurs reach success.
Dr. Siegall’s career began at Bristol-Myers Squibb Pharmaceutical Research Institute followed by the National Institutes of Health, the National Cancer Institute. He currently is the president, chief executive officer and chairman of the board at Seattle Genetics, which he co-founded.
He has directed the company to a dominant position in antibody-drug-conjugates (ADCs). In 2011 the company’s first ADC product, ADCETRIS, received approval from the Food And Drug Administration (FDA).
Dr. Siegall, who possesses 15 patents, has authored more than 70 publications. He also serves as a director on the board at Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable.